Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.79 |
| ▸ | CLK2 | P49760 | 1/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TOP1 | P11387 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761508 | 1.00 | KDM4E (0.79) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| SCHEMBL10863651 | 0.91 | KDM4E (0.64) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| Hydrochloric Acid SCHEMBL4713001 | 0.90 | KDM4E (0.64) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL2224369 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL22591 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL22592 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL30910969 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL29356306 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| (R)-Gatifloxacin SCHEMBL5670068 | 0.88 | KDM4E (1.00) | KDM4EHPGDALDH1A1KCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL4820507 | 0.88 | KDM4E (0.89) | KDM4EHPGDALDH1A1KCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1262477-B1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI SANKYO CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1262477-A1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | PGD, PPA1, FASTKD1 | KDM4E 3677/4885HPGD 146/4885ALDH1A1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.